Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 3/20 | 0.63 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.51 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.48 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.48 |
| ▸ | MYLK | Q15746 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20290499 | 0.91 | MELK (0.74) | MELKLRRK2MEN1KMT2AROCK2 | |
| SCHEMBL20291184 | 0.85 | MELK (0.66) | MELKLRRK2ROCK2ROCK1SGMS2 | |
| SCHEMBL4936884 | 0.82 | LRRK2 (0.69) | LRRK2MEN1KMT2ASGMS2LMNA | |
| SCHEMBL20291125 | 0.81 | MELK (0.73) | MELKLRRK2ROCK2ROCK1SGMS2 | |
| SCHEMBL20290495 | 0.80 | MELK (0.58) | MELKLRRK2MEN1KMT2AROCK2 | |
| SCHEMBL3722812 | 0.78 | MELK (0.55) | MELKLRRK2ROCK2ROCK1MKNK2 | |
| SCHEMBL1649389 | 0.78 | LRRK2 (0.84) | LRRK2SGMS2 | |
| SCHEMBL20291124 | 0.76 | MELK (0.52) | MELKLRRK2ROCK2ROCK1FLT3 | |
| SCHEMBL20290501 | 0.75 | LRRK2 (0.75) | MELKLRRK2MEN1KMT2ASGMS2 | |
| SCHEMBL20291171 | 0.74 | SGMS2 (0.74) | LRRK2MEN1KMT2ASGMS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875844-B2 | Salicylate inhibitors of MELK and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875844-B2 | Salicylate inhibitors of MELK and methods of use | MELK, HIPK3, MINK1 | MELK 1/4885LRRK2 177/4885MEN1 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.